December 21, 2014 10:25 AM ET

Healthcare Providers and Services

Company Overview of NovaMed Pharmaceuticals Inc.

Executive Profile

Mark Lotter

Former Chief Executive Officer of China Operations and Director, SciClone Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.

50--
As of Fiscal Year 2012

Background

Mr. Mark Lotter was the Chief Executive Officer of China Operations at SciClone Pharmaceuticals, Inc., from April 2011 to December 14, 2012. Mr. Lotter was the Chief Executive Officer, President, and Director at NovaMed Pharmaceuticals Inc. Prior to founding NovaMed, Mr. Lotter served as Vice President, Commercial Operations of AstraZeneca China. He was largely responsible for turning AstraZeneca to the largest prescription based multinational in China. He served as ...

Corporate Headquarters

Room 2601
Shanghai, -- 200003

China

Phone: 86 21 6375 9333
Fax: 86 21 6375 8810

Board Members Memberships

Chief Executive Officer, President, and Director
2011-2012
Former Chief Executive Officer of China Operations and Director

Education

BS
The University of KwaZulu-Natal
MBA
University of South Africa

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Christopher Nishan Garabedian Chief Executive Officer, President and Director
Sarepta Therapeutics, Inc.
$580.0K
Arthur P. Bedrosian J.D.Chief Executive Officer, Director and Chairman of Strategic Planning Committee
Lannett Company, Inc.
$539.0K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$621.0K
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
--
Jeffrey M. Yordon Founder, Chairman and Chief Executive Officer
Sagent Pharmaceuticals, Inc.
$615.2K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NovaMed Pharmaceuticals Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.